Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Mavacamten to treat patients with obstructive HCM in Portugal – an interim analysis of the MAVA-PT cohort
Session:
Sessão de Comunicações Orais 14 – Mavacamten na MCH obstrutiva: preditores de resposta, remodelagem e dados de vida real
Speaker:
Débora Da Silva Correia
Congress:
CPC 2026
Topic:
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Theme:
17. Myocardial Disease
Subtheme:
17.4 Myocardial Disease – Treatment
Session Type:
Comunicações Orais
FP Number:
---
Authors:
Débora da Silva Correia; Inês Miranda; Julien Lopes; Sérgio Maltês; Filipa Gerardo; Rodrigo Brandão; José Viegas; Tânia Laranjeira; João Bicho Augusto; Sílvia Aguiar; Bruno Rocha
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="font-size:12.0pt"><span style="font-family:"Times New Roman",serif">Background: </span></span></strong><span style="font-size:12.0pt"><span style="font-family:"Times New Roman",serif">Mavacamten, a selective cardiac myosin inhibitor, reduces left ventricular outflow tract obstruction (LVOTO) while improving exercise capacity and symptoms in patients with obstructive hypertrophic cardiomyopathy (oHCM). As a drug becomes more widely used, generating real-world data is important to assess its effectiveness and safety. MAVA-PT is an observational multicentre study aiming to assess patient characteristics, treatment patterns, and longitudinal outcomes in patients receiving mavacamten.</span></span></span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="font-size:12.0pt"><span style="font-family:"Times New Roman",serif">Aim:</span></span></strong><span style="font-size:12.0pt"><span style="font-family:"Times New Roman",serif"> To describe the real-world experience with the use of mavacamten in symptomatic oHCM across Portuguese centres.</span></span></span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="font-size:12.0pt"><span style="font-family:"Times New Roman",serif">Methods:</span></span></strong><span style="font-size:12.0pt"><span style="font-family:"Times New Roman",serif"> All consecutive adult patients with symptomatic (NYHA III) oHCM enrolled in the Early Access Program at 3 centres were analysed in this interim analysis. Baseline characteristics, clinical outcomes, and safety were compared with the EXPLORER-HCM and VALOR-HCM trials.</span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="font-size:12.0pt"><span style="font-family:"Times New Roman",serif">Results: </span></span></strong><span style="font-size:12.0pt"><span style="font-family:"Times New Roman",serif">Overall, ninety-three patients were included [mean age 65 ± 12 years; 31% male; 91% beta-blocker at baseline; 6 patients with prior septal reduction therapy]. Pathogenic or likely pathogenic variants were identified in 18% patients of those genotyped (16/87). Only two patients were poor CYP2C19 metabolizers. MAVA-PT patients presented with a higher symptom burden and LVOTO than those in the EXPLORER-HCM and VALOR-HCM. </span></span></span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Times New Roman",serif">Seventy-three patients had received at least one month of mavacamten and were included for further analysis. At a median follow-up of 9 (3-14) months, a significant improvement was noted in functional capacity (NYHA I: 0 vs. 73%; p<0.001), NT-proBNP (1012 [301-2368] vs. 235 [103-491] pg/mL; p<0.001), maximal LVOTO (99 ± 41 vs. 24 ± 30 mmHg; p<0.001) and maximal wall thickness (18 [16-21] vs. 16 [15-18] mm; p<0.001). Maximal LVOTO below 30 mmHg and 50 mmHg was achieved in 48 (66%) and 60 (82%) of the patients at last follow-up, respectively, all of whom had an improvement of at least one NYHA class. These changes were comparable to those in observed in the EXPLORER-HCM and VALOR-HCM trials (<strong><span style="color:#0070c0">central figure</span></strong>).</span></span></span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:"Times New Roman",serif">Mavacamten was well-tolerated, with low adverse event rates. There was a mild reduction in left ventricular ejection fraction (LVEF) (67 ± 8% vs. 63 ± 8%; p<0.001). Nine patients discontinued mavacamten due to a LVEF <50%, all of whom had fully recovered LVEF after 4 weeks and seven of whom were restarted on treatment. Three additional patients stopped the drug: one due to planned pregnancy, one due to generalized muscle weakness and one for a non-cardiovascular death. There were no reported arrhythmic events.</span></span></span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="font-size:12.0pt"><span style="font-family:"Times New Roman",serif">Conclusion:</span></span></strong><span style="font-size:12.0pt"><span style="font-family:"Times New Roman",serif"> MAVA-PT is the first real-world study characterizing the use of mavacamten in patients with oHCM in Portugal. This interim analysis provides insight of the national experience with the drug, showing substantial clinical and structural improvements and a favourable safety profile.</span></span></span></span></p>
Our mission: To reduce the burden of cardiovascular disease
Visit our site